Silk Road Medical, Inc Stock

Equities

SILK

US82710M1009

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-05-17 pm EDT 5-day change 1st Jan Change
22.18 USD -1.20% Intraday chart for Silk Road Medical, Inc +5.47% +80.77%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 197M Sales 2025 * 218M Capitalization 875M
Net income 2024 * -54M Net income 2025 * -52M EV / Sales 2024 * 4.38 x
Net cash position 2024 * 11.13M Net cash position 2025 * 41.33M EV / Sales 2025 * 3.82 x
P/E ratio 2024 *
-16.2 x
P/E ratio 2025 *
-16.9 x
Employees 474
Yield 2024 *
0.57%
Yield 2025 *
-
Free-Float 95.74%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Silk Road Medical, Inc Presents at Bank of America Health Care Conference 2024, May-14-2024 through May-16-2024
Transcript : Silk Road Medical, Inc, Q1 2024 Earnings Call, Apr 30, 2024
Earnings Flash (SILK) SILK ROAD MEDICAL Reports Q1 Revenue $48.5M, vs. Street Est of $44.7M MT
Silk Road Medical, Inc Provides Revenue Guidance for the Full Year 2024 CI
Silk Road Medical, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuro Protection System Plus CI
North American Morning Briefing : Stock Futures -2- DJ
Silk Road Medical Inc. and Genesis MedTech Group have signed an exclusive distribution agreement to introduce the TCAR® core products CI
Argus Upgrades Silk Road Medical to Buy From Hold, Price Target is $24 MT
Silk Road Medical Expands TCAR Portfolio with Launch of Tapered Enroute®? Transcarotid Stent System CI
Piper Sandler Raises Price Target on Silk Road Medical to $18 From $11, Maintains Neutral Rating MT
Transcript : Silk Road Medical, Inc, Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (SILK) SILK ROAD MEDICAL Reports Q4 Revenue $47.3M, vs. Street Est of $42M MT
Silk Road Medical, Inc Provides Revenue Guidance for the Full Year 2024 CI
Silk Road Medical, Inc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
More news
1 day-1.20%
1 week+5.47%
Current month+14.09%
1 month+27.32%
3 months+21.53%
6 months+160.94%
Current year+80.77%
More quotes
1 week
20.58
Extreme 20.58
22.89
1 month
16.40
Extreme 16.4
22.89
Current year
11.05
Extreme 11.05
22.89
1 year
6.08
Extreme 6.08
34.13
3 years
6.08
Extreme 6.08
67.49
5 years
6.08
Extreme 6.08
75.80
10 years
6.08
Extreme 6.08
75.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 Nov. 01
Director of Finance/CFO 46 09-07-31
Chief Tech/Sci/R&D Officer - 20-09-20
Members of the board TitleAgeSince
Director/Board Member 56 18-03-25
Director/Board Member 51 20-12-02
Chairman 70 07-03-31
More insiders
Date Price Change Volume
24-05-17 22.18 -1.20% 491,374
24-05-16 22.45 +3.65% 712,039
24-05-15 21.66 +2.70% 429,262
24-05-14 21.09 +1.79% 495,414
24-05-13 20.72 -1.47% 384,403

Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT

More quotes
Silk Road Medical, Inc. is a medical device company that is focused on reducing the risk of stroke and its impact. The Company has developed an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. Its product portfolio consists of five single-use components: ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014'' Guidewire and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. It manufactures ENROUTE NPS and ENROUTE NPS PLUS, or its ENROUTE NPS products, at its facilities in Sunnyvale, California and Plymouth, Minnesota. These facilities provide an aggregate of over 35,000 square feet of space for its production and distribution operations.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
22.18 USD
Average target price
19 USD
Spread / Average Target
-14.34%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW